REG - Celadon Pharma. PLC - Change of Website Address

Celadon PharmaceuticalsAnnouncement

19/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230119:nRSS1761Na&default-theme=true

RNS Number : 1761N  Celadon Pharmaceuticals PLC  19 January 2023

 

 

Celadon Pharmaceuticals Plc

 

Change of Website Address

 

London, 19 January 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), announces
that its website address has changed to www.celadonpharma.com with immediate
effect.  The information required pursuant to AIM Rule 26 can be found at
this address.

 

Enquiries:

 

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Arthur Wakeley

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts / Patrick Dolaghan          +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /             +44 (0)20 7250 1446

 Ibrahim Khalil

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility comprises a laboratory designed to meet GMP standards, and
capacity for a large indoor hydroponic growing facility that has received a
Home Office Licence to legally grow high-THC medicinal cannabis for the
purpose of producing test batches of cannabis oil to support its application
to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved
cannabis trial using cannabis based medicinal products to treat chronic pain
in the UK.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFVRLTITLIV